Reuters logo
BRIEF-Abbvie submits application to FDA for chronic Hepatitis C treatment
December 19, 2016 / 1:31 PM / 9 months ago

BRIEF-Abbvie submits application to FDA for chronic Hepatitis C treatment

Dec 19 (Reuters) - Abbvie Inc

* Abbvie is on track to submit a marketing authorization application for g/p in european union in early 2017

* Abbvie submits new drug application to u.s. Fda for its investigational regimen of glecaprevir/pibrentasvir (g/p) for the treatment of all major genotypes of chronic hepatitis c Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below